The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309).
The work provided the first genetic proof for a completely new and rational treatment for osteoporosis, one of the most serious public health problems for older women. The results of phase III clinical trials for a human antibody to RANKL have recently been published (see Cummings et al. 2009, New Eng. J. Med. 361, 756-765) and, pending approval by the authorities, it is conceivable that this antibody will soon be made widely available for osteoporosis treatment.
Considering that such treatments might be of potential benefit to millions of patients, it is important to understand any possible side-effects and in this regard the old observation (see Kartsogiannis et al. 1999, Bone 25, 525-534) that RANKL is also expressed in the brain is highly interesting. The function of RANK and RANKL in the brain was completely unknown and forms the basis of Penninger's latest work. To investigate it, Reiko Hanada - an endocrinologist and Postdoc in Penninger's group - injected RANKL into mice and rats, intending to look for effects on behaviour. As Penninger says, "in principle the injections could have resulted in changes to the animals' intelligence or memory or in subtle behavioural alterations that we could never have detected. But we were lucky. The results were dramatic and obvious - the animals stopped moving and developed really high temperatures."
That this was not mere coincidence was suggested by the observation that RANK and RANKL are not present in all areas of the brain. Rather, the proteins were found to be restricted to areas that other groups had previously implicated in the control of body temperature. And Penninger's group showed further that injections of RANKL triggered changes in areas of the brain known to be involved in the fever response, through which mammals increase their body temperature to fight infection. Unlike normal mice, mice that had been engineered to lack RANK in the brain did not respond to simulated infections by raising their body temperature although they appeared otherwise normal. Taken together, these results show that RANK and its ligand are involved in the regulation of the body's fever response to fight infections.
Because Penninger's group had previously shown that RANK and RANKL control the production of milk during pregnancy, it seemed possible that the system might also have an effect on the body temperature of females. Penninger freely concedes that "this was a hunch but one that seemed worth checking." And his speculation turned out to be correct: female - but not male - mice lacking RANK in the brain show a significant increase in body temperature compared with their littermates, at least during daylight hours. As a result, such female mice have much lower differences in body temperature between day and night. In a final experiment, this effect was revealed to be at least partially the result of sex hormones released from the ovaries.